NASDAQ:GH Guardant Health Q3 2026 Earnings Report $179.69 +1.96 (+1.10%) As of 02:07 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Guardant Health EPS ResultsActual EPSN/AConsensus EPS -$0.75Beat/MissN/AOne Year Ago EPSN/AGuardant Health Revenue ResultsActual RevenueN/AExpected Revenue$350.70 millionBeat/MissN/AYoY Revenue GrowthN/AGuardant Health Announcement DetailsQuarterQ3 2026Date10/28/2026TimeAfter Market ClosesConference Call DateWednesday, October 28, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Guardant Health Earnings HeadlinesGuardant Health (GH)September 29 at 7:48 AM | es.investing.comGuardant Health (GH) Receives a Buy from BernsteinSeptember 27 at 2:07 PM | theglobeandmail.comLegendary U.S. Congressman Issues WarningDr. Ron Paul warns a dangerous experiment is already underway in Washington, involving at least 27 billion dollars and roughly 30 U.S. companies. Some stocks tied to this shift have already fallen 50% or more, Paul says, as the relationship between government and the stock market changes.September 30 at 1:00 AM | Altimetry (Ad)Guardant Health, Inc. (NASDAQ:GH) Stock Has Consensus Price Target of $188.12 According to AnalystsSeptember 27 at 2:44 AM | americanbankingnews.comGuardant Health Inc (GH)September 26, 2026 | za.investing.comReviewing The Pennant Group (NASDAQ:PNTG) & Guardant Health (NASDAQ:GH)September 23, 2026 | americanbankingnews.comSee More Guardant Health Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Guardant Health? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Guardant Health and other key companies, straight to your email. Email Address About Guardant HealthGuardant Health (NASDAQ:GH) (NASDAQ: GH) is a precision oncology company that develops blood- and tissue-based diagnostic tests designed to help detect cancer, guide treatment decisions and monitor patients throughout the course of their disease. Its testing platforms analyze circulating tumor DNA and other genomic information to provide insights into a tumor’s molecular characteristics. The company’s products include Guardant360 tests for comprehensive genomic profiling in advanced cancer, Guardant360 CDx, which is approved as a companion diagnostic for certain targeted therapies, and Guardant360 Response for assessing how a tumor may be responding to treatment. Guardant also offers Guardant Reveal, a blood-based test intended to help evaluate minimal residual disease and recurrence risk, as well as Shield, a blood test for colorectal cancer screening. Guardant Health provides testing services to physicians, hospitals, health systems, biopharmaceutical companies and research organizations. Its services support patient care, clinical research and drug development, with operations and commercial activities serving customers in the United States and international markets. The company was founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, who have held senior leadership roles at Guardant Health. The company is headquartered in Palo Alto, California.View Guardant Health ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles CarMax Just Gave Investors a Better Reason to Believe in the TurnaroundArhaus Has New Momentum—Could Other Furniture Stocks Be Next?Bernstein Downgrades 3 Cybersecurity Stocks: How Concerned Should Investors Be?Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks3 Stocks Under the Microscope After Large Insider Sales Upcoming Earnings NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
